Exploring the Value and Path Forward for Brain-Computer Interfaces: From Technical Validation to Commercialization — China Innovative Healthcare Assets Salon | Transaction Roundtable Session 22

Focused on financial advisory work in the biomedicine and healthcare sector for many years. Led financing for 40+ projects, with a total transaction value of over 6 billion yuan. Cases include: HaiChuang Pharma, RunSheng Pharma, VivaVision Bio, ChangXi Pharma, ZhiRan Medical, RosenBot, ChromaLab, RaylioTech, DingChi Bio, BoRuiDi, QiHe Bio, etc.

With a comprehensive and deep cooperation network, successfully collaborated investors include top-tier dual-currency funds such as Sequoia, Hillhouse, IDG, Legend Capital, and SoftBank; leading medical professional institutions like Lapam, Huagai, Puhua, Gortica, and Yuansheng; large PE firms including Tianyi, China Merchants Group, China Life, CPE; industrial players like Medtronic, CRRC, Alibaba; as well as local government funds such as Beijing Municipal Pharmaceutical and Robotics Industry Funds, etc.

Bachelor's and Master's degrees from Tongji Medical College, Huazhong University of Science and Technology (Biopharmaceutics & Pharmacology), Visiting Scholar at the University of Iowa, USA (Pharmaceutics). Participated in the research of the 14th Five-Year Plan for the Development of Medical Equipment Industry by the Ministry of Industry and Information Technology; Outstanding Young Financial Advisor U35 in 2023.

Major in Management at Zhejiang University, Digital Healthcare Management EMBA at Tsinghua University, specially appointed researcher at the Zhejiang University Innovation Technology Research Institute, General Manager of the healthcare system business unit at Zhejiang University Network New Technology Co., Ltd., PhD at Beijing Jiahemeikang Co., Ltd. Director and Co-founder of Zhejiang Roulin Technology Co., Ltd., CMO of Mindtrix Technology (Suzhou) Co., Ltd. Long-term engagement in commercialization practices spanning research-clinical-market in digital healthcare, healthcare informatization, and brain-computer interface fields; industry strategy research, market development and brand building, as well as government and industry association support and exchange.

Master's degree from Tsinghua University. Currently serves as the General Manager of Investment Business at Mingxi Capital and as a director on the boards of several invested companies. Mingxi Capital, jointly established by the listed company Mindray Bioelectronics and Legend Capital, focuses on healthcare investments. Possesses extensive experience in healthcare industry investments and investment banking, leading the IPOs and investments of representative projects across various medical fields such as innovative devices and consumer health.

Currently serving as the Product Director of the Brain Science Laboratory at Xiangyu Rehabilitation Technology Research Institute, a member of the First Committee on Brain-Computer Interface and Rehabilitation of the Tianjin Rehabilitation Medical Association, and a member of the China Brain-Computer Interface Technology Innovation and Industry Service Alliance.

15 years of experience in medical device product development, 13 invention patents, and has successively won the Excellence Award in the final of China Medical Device Innovation and Entrepreneurship Competition (Artificial Intelligence Group), the Excellence Award in the finals of the 8th and 9th China Innovation and Entrepreneurship Competitions for SMEs Integration Professional Track, the First Prize in the 2020 Shanghai International Maker Competition, and the Third Prize in the 2020 Lian'an Yangtze River Delta High-level Talent Innovation and Entrepreneurship Competition.

Research Direction: Application of Non-Invasive Brain-Computer Interface in Functional Electrical Stimulation-Assisted Therapy and Intervention for Swallowing Disorders Related to Neurological Diseases.